SG Americas Securities’s Eterna Therapeutics ERNA Stock Holding History

SG Americas Securities’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$103K	–	3506
2021 Q3	$103K	Buy	+1	New	+$86.3K	﹤0.01%	3654

Other funds holding ERNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SG Americas Securities's ERNA Position: Q4 2021 in Review

SG Americas Securities sold out of Eterna Therapeutics (ERNA) in Q4 2021, closing a stake of 1 share — an estimated $103K sold.

SG Americas Securities first reported a position in ERNA in Q3 2021 and held it in 1 quarter. The position peaked at $103K in Q3 2021. 47 funds tracked by Wall St. Rank hold ERNA as of Q4 2021.

SG Americas Securities reported no remaining Eterna Therapeutics position as of Q4 2021 after selling out during the quarter.
SG Americas Securities sold 1 Eterna Therapeutics share in Q4 2021, an estimated $103K.
SG Americas Securities first reported a position in Eterna Therapeutics in Q3 2021 and held it in 1 quarter.
SG Americas Securities's Eterna Therapeutics position peaked at $103K in Q3 2021.
47 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.